Trial Profile
Phase I trial of SCIB-1 companion diagnostic [ImmunTraCkeR] to investigate the immune-modulatory effect of SCIB-1 vaccine [ImmunoBody] in patients with stage III/IV metastatic melanoma
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 10 Aug 2015
Price :
$35
*
At a glance
- Drugs SCIB 1 (Primary)
- Indications Malignant melanoma
- Focus Diagnostic use
- 10 Aug 2015 New trial record
- 30 Jul 2015 Scancell and ImmunID have entered into an agreement to collaborate on a study of SCIB-1 companion diagnostic [ImmunTraCkeR] to investigate the immune-modulatory effect of SCIB-1 vaccine [ImmunoBody] in patients with stage III/IV metastatic melanoma.